<?xml version="1.0" encoding="UTF-8"?>
<p id="p0135">The international societies, including the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL), do not provide specific guidelines on indications for chronic HDV treatment.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib21" ref-type="bibr">
  <sup>21</sup>
 </xref> The decision to treat with interferon must be balanced between the suspected degree of inflammation and fibrosis and whether the trajectory of disease warrants the potential side effects from interferon therapy and expected low response rates. Although the presence of HDV typically suppresses HBV replication,
 <xref rid="bib22" ref-type="bibr">
  <sup>22</sup>
 </xref> treatment with a nucleoside/nucleotide analogue (entecavir or tenofovir) is generally recommended for co-infected patients with HBV DNA levels greater than 2000 IU/mL and all patients with cirrhosis regardless of HBV replication status (
 <xref rid="tbl2" ref-type="table">Table 2</xref> ).
</p>
